Johnson & Johnson (JNJ) Intangibles (2009 - 2026)
Johnson & Johnson (JNJ) posted Intangibles of $48.2 billion for Q2 2026, down 1.7% sequentially from $49.1 billion in Q1 2026, and down 3.22% YoY from $49.8 billion in Q2 2025.
Johnson & Johnson (JNJ) Intangibles (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Intangibles for 18 years, with the latest figure at $48.2 billion in Q2 2026.
- Quarterly Intangibles fell 3.22% year-over-year to $48.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $48.2 billion (down 3.22% YoY) and the FY2025 annual result came in at $50.4 billion, up 33.99% from the prior year.
- Intangibles eased to $48.2 billion in Q2 2026 per JNJ's latest filing, from $49.1 billion in the prior quarter.
- Over five years, Intangibles peaked at $50.4 billion in Q4 2025 and troughed at $34.2 billion in Q4 2023.
- A 5-year average of $42.6 billion and a median of $42.4 billion in 2022 frame the typical range for Intangibles.
- The sharpest annual moves came in 2024 and 2025: Intangibles dropped 27.74% in 2024, then surged 33.99% in 2025.
- Over 5 years, Intangibles stood at $40.3 billion in 2022, then fell by 15.27% to $34.2 billion in 2023, then advanced by 10.07% to $37.6 billion in 2024, then soared by 33.99% to $50.4 billion in 2025, then slipped by 4.31% to $48.2 billion in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $48.2 billion, $49.1 billion, and $50.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 30.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 48.23 Bn |
| Mar 29, 2026 | 49.06 Bn |
| Dec 28, 2025 | 50.40 Bn |
| Sep 28, 2025 | 48.74 Bn |
| Jun 29, 2025 | 49.84 Bn |
| Mar 30, 2025 | 36.76 Bn |
| Dec 29, 2024 | 37.62 Bn |
| Sep 29, 2024 | 39.49 Bn |
| Jun 30, 2024 | 39.73 Bn |
| Mar 31, 2024 | 34.29 Bn |
| Dec 31, 2023 | 34.18 Bn |
| Oct 1, 2023 | 35.02 Bn |
| Jul 2, 2023 | 46.25 Bn |
| Apr 2, 2023 | 47.45 Bn |
| Jan 1, 2023 | 38.49 Bn |
| Oct 2, 2022 | 40.34 Bn |
| Jul 3, 2022 | 42.41 Bn |
| Apr 3, 2022 | 44.42 Bn |
| Jan 2, 2022 | 46.39 Bn |
| Oct 3, 2021 | 47.78 Bn |